{"id":"NCT01302119","sponsor":"Pfizer","briefTitle":"Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","officialTitle":"A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-12-31","completion":"2013-02-20","firstPosted":"2011-02-23","resultsPosted":"2014-08-15","lastUpdate":"2019-04-03"},"enrollment":604,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Onychomycosis of Toenails"],"interventions":[{"type":"DRUG","name":"AN2690 Topical Solution, 5%","otherNames":[]},{"type":"DRUG","name":"Solution Vehicle","otherNames":[]}],"arms":[{"label":"AN2690 Topical Solution, 5%","type":"EXPERIMENTAL"},{"label":"Solution Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.","primaryOutcome":{"measure":"Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"AN2690 Topical Solution, 5%","deltaMin":36,"sd":null},{"arm":"Solution Vehicle","deltaMin":3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":32,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":395},"commonTop":["Tinea pedis","Nasopharyngitis","Upper respiratory tract infection"]}}